Shire ulcerative colitis drug gets FDA nod
The FDA approval was given on the basis of the results from a six-month study, which demonstrated that the drug is safe and effective in maintaining endoscopic remission
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.